What we bring
- Recombinant proteins developed for an array of dreaded infectious diseases encompassing prophylactics and therapeutics.
- The platform technology can be used for the development of number of products.
- Does not require highly contained manufacturing infrastructure (BSL-3 and beyond).
- Campaign-based production possible for each of the platform technology enabling capacity utilization and economies of scale.
- All products developed in compliance with ICH Q series and specific CTD modules.
- Each of the candidate developed would have an FTO or novelty with appropriate IP.
- BioGrit Technologies has expertise across different domains as shown below in Figure 10.
Functions | Description |
Research & Development |
|
Preclinical studies |
|
Clinical Trials |
|
Strategic Regulatory Affairs |
|
Global Business Development and Strategy |
|
Intellectual Property &
Legal compliance |
|
Medical Affairs |
|